β2-Adrenergic receptor agonist enhances the bystander effect of HSV-TK/GCV gene therapy in glioblastoma multiforme via upregulation of connexin 43 expression.
bystander effect
connexin 43
gene therapy
glioblastoma multiforme
olfactory ensheathing cells
β2-adrenergic receptor
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
15 Sep 2022
15 Sep 2022
Historique:
received:
21
12
2021
accepted:
27
05
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
8
7
2022
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is the most invasive form of primary brain astrocytoma. Gene therapy using the herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) is a new strategy for GBM treatment. As the connexin 43 (Cx43) levels are downregulated in GBM cells, it seems that the upregulation of Cx43 could improve the efficacy of the gene therapy. This study aims to evaluate the effect of clenbuterol hydrochloride (Cln) as a β2-adrenergic receptor agonist on HSV-TK/GCV gene therapy efficacy in human GBM cells using olfactory ensheathing cells (OECs) as vectors. The lentivirus containing the thymidine kinase gene was transduced to OECs and the effective dose of GCV on cells was measured by MTT assay. We found that Cln upregulated Cx43 expression in human GBM cells and OECs and promoted the cytotoxic effect of GCV on the co-culture cells. Western blot results showed that Cln increased the cleaved caspase-3 expression and the Bax/Bcl2 ratio in the co-culture of GBM cells and OEC-TK. Also, the flow cytometry results revealed that Cln increased apoptosis in the co-culture of GBM cells and OEC-TK cells. This study showed that Cln via upregulation of Cx43 expression could enhance the bystander effect of HSVTK-GCV gene therapy in human GBM cells.
Identifiants
pubmed: 35795095
doi: 10.1016/j.omto.2022.05.010
pii: S2372-7705(22)00076-6
pmc: PMC9233183
doi:
Types de publication
Journal Article
Langues
eng
Pagination
76-87Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Medicina (Kaunas). 2010;46(1):1-12
pubmed: 20234156
J Cell Physiol. 2017 Jul;232(7):1596-1601
pubmed: 27458813
Stem Cell Reports. 2017 Aug 8;9(2):451-463
pubmed: 28712848
Hum Gene Ther. 1999 Mar 1;10(4):679-88
pubmed: 10094211
Mol Med Rep. 2017 Jul;16(1):764-772
pubmed: 28560395
Cancer Biother Radiopharm. 2019 Aug;34(6):345-354
pubmed: 31411929
Oncogene. 2005 Feb 10;24(7):1231-43
pubmed: 15592511
Biochem Biophys Res Commun. 2012 May 11;421(3):585-90
pubmed: 22525671
Cancers (Basel). 2013 Aug 14;5(3):1049-71
pubmed: 24202333
Int J Mol Sci. 2020 Mar 12;21(6):
pubmed: 32178267
Adv Pharm Bull. 2019 Jun;9(2):205-218
pubmed: 31380246
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Oncotarget. 2016 Aug 2;7(31):49819-49833
pubmed: 27391443
PLoS One. 2013 Jul 04;8(7):e67662
pubmed: 23861780
J Cell Physiol. 2001 Apr;187(1):22-36
pubmed: 11241346
Basic Clin Neurosci. 2015 Jan;6(1):52-7
pubmed: 27504157
Oncogene. 2018 Mar;37(9):1121-1141
pubmed: 29242608
Oncol Rep. 2013 Apr;29(4):1435-40
pubmed: 23354806
Int J Clin Exp Pathol. 2015 May 01;8(5):4296-306
pubmed: 26191122
Br J Cancer. 2015 Jul 14;113(2):259-67
pubmed: 26135897
Gene Ther. 1999 Mar;6(3):420-31
pubmed: 10435092
Cancer Gene Ther. 2011 Sep;18(9):674-81
pubmed: 21779029
Int J Cancer. 2002 Dec 1;102(4):328-33
pubmed: 12402300
Semin Cancer Biol. 2004 Aug;14(4):231-43
pubmed: 15219616
Exp Ther Med. 2019 Mar;17(3):1649-1655
pubmed: 30783433
Biochim Biophys Acta. 2012 Aug;1818(8):2058-67
pubmed: 22063721
Nanomaterials (Basel). 2019 Jan 16;9(1):
pubmed: 30654536
Int J Mol Sci. 2018 Jan 02;19(1):
pubmed: 29301329
PLoS One. 2021 Aug 9;16(8):e0253008
pubmed: 34370752
Brain Struct Funct. 2017 May;222(4):1877-1895
pubmed: 27718014
FASEB J. 2006 Feb;20(2):365-7
pubmed: 16352648
Acta Pharmacol Sin. 2009 Jul;30(7):928-34
pubmed: 19574999
PeerJ. 2019 Sep 20;7:e7760
pubmed: 31579620
Eur Arch Otorhinolaryngol. 2009 Nov;266(11):1675-80
pubmed: 19714350
Hum Gene Ther. 2000 Nov 20;11(17):2389-401
pubmed: 11096443
Br J Cancer. 2021 Feb;124(4):697-709
pubmed: 33144698
J Biol Chem. 1999 Jan 22;274(4):2225-33
pubmed: 9890985
Am J Pathol. 1997 Mar;150(3):805-14
pubmed: 9060818
J Cell Mol Med. 2020 Aug;24(15):8505-8517
pubmed: 32578931
Cancers (Basel). 2013 Oct 23;5(4):1271-305
pubmed: 24202446
Cardiovasc Res. 2001 Oct;52(1):95-102
pubmed: 11557237
Development. 2018 May 14;145(10):
pubmed: 29759978
Neurosci Lett. 2014 Jul 11;575:19-24
pubmed: 24858134
Front Mol Neurosci. 2019 Feb 06;12:23
pubmed: 30787868
Cancer Gene Ther. 2010 Mar;17(3):192-202
pubmed: 19851353
Mol Med Rep. 2017 Dec;16(6):7890-7900
pubmed: 28983585
Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8039-43
pubmed: 1654555
Cell Rep. 2015 May 19;11(7):1031-42
pubmed: 25959821
Neuro Oncol. 2015 Mar;17 Suppl 2:ii24-ii36
pubmed: 25746089
Discov Med. 2010 Oct;10(53):293-304
pubmed: 21034670
Mol Med Rep. 2015 Aug;12(2):1941-50
pubmed: 25873300
Semin Cancer Biol. 2022 Jul;82:176-183
pubmed: 33453403
Mol Med Rep. 2014 Jun;9(6):2405-10
pubmed: 24714982
Mol Neurobiol. 2016 Oct;53(8):5118-28
pubmed: 26395282
Cancer Lett. 1995 Sep 4;96(1):105-10
pubmed: 7553597
Cell Res. 2008 Apr;18(4):479-90
pubmed: 18347613
Biochim Biophys Acta. 2011 Jan;1815(1):13-25
pubmed: 20801193
J Mol Neurosci. 2020 Oct;70(10):1451-1460
pubmed: 32506304
Nat Commun. 2019 Jun 11;10(1):2541
pubmed: 31186414
Oncotarget. 2019 Oct 22;10(58):6049-6061
pubmed: 31692882